Tier 2 — strong
Absorption Study of Mozuku Fucoidan in Japanese Volunteers
Marine Drugs
2018
16(8):254
Bibliography
- PubMed
- PMID 30061499
- PubMed Central
- PMC6117716
- Funding
- The authors reported no external funding.
- Competing interests
- The authors declared no conflict of interest. Three authors were affiliated with South Product Co., Ltd.
Study snapshot
| Design | Human oral administration and absorption study |
|---|---|
| Model | Japanese adult volunteers |
| Sample | 396 |
| Intervention | Single oral 3 g dose of mozuku fucoidan with urine collection at 0, 3, 6 and 9 hours |
| Duration | 9-hour post-dose sampling |
| Endpoints | Urinary fucoidan detection; Estimated fucoidan excretion; Association with habitual mozuku intake; Regional differences in absorption |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Citation network
Articles citing this research paper
Biohack Blueprint analyses that reference this study in their evidence base.
- Fucoidan Safety: Human Trials, Bleeding Risk & Drug InteractionsFucoidan safety explained from human studies: side effects, anticoagulant concerns, absorption, medication interactions, pregnancy and dose limitations.Read analysis
- SIRT6 Activator Dosage: Manufacturer Guidance vs Human Trial DosesSIRT6 activator dosage explained: DoNotAge’s 800–2,400 mg guidance, the 2.4 g human trial dose, timing, capsules and what research can actually support.Read analysis
- Fucoidan SIRT6 Activator: The Evidence, In Mice and HumansFucoidan is the leading natural SIRT6 activator candidate. Mouse and mechanistic evidence has now progressed into human testing, including NUS PROMETHEUS and...Read analysis
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
